Menu

AbbVie Inc. (ABBV)

$228.13
+3.00 (1.33%)

Data provided by IEX. Delayed 15 minutes.

Market Cap

$403.0B

P/E Ratio

78.2

Div Yield

2.91%

52W Range

$159.36 - $242.62

Company Profile

At a glance

AbbVie's Q1 2025 performance significantly exceeded expectations, driven by robust growth from its ex-Humira portfolio, demonstrating successful diversification beyond its former flagship product.

The immunology powerhouses Skyrizi and Rinvoq continue to deliver exceptional sales growth, fueled by strong market share gains across multiple indications and compelling clinical differentiation, leading to raised full-year guidance for both assets.

Strategic acquisitions in Neuroscience (Cerevel) and Oncology (ImmunoGen) are yielding promising pipeline assets and commercial products (Elahere, Teliso-V, Tavapadon, Vyalev), contributing meaningfully to current and future growth.

Price Chart

Loading chart...

The most compelling investment themes are the ones nobody is talking about yet.

Every Monday, get three under-the-radar themes with catalysts, data, and stocks poised to benefit.

Sign up now to receive them!

Also explore our analysis on 5,000+ stocks